ACC/AHA '14 scheme will be noted as strength of rec. +/- level of evidence
Strength of Recommendations
Class I: Benefit >>> Risk
item (treatment, test) SHOULD be performed
Class Ila: Benefit >> Risk
item REASONABLE to perform
Class llb: Benefit 2 Risk
item MAY BE CONSIDERED
Class III:NB No Benefit
item SHOULD NOT be performed, no benefit
Class III:H Harm
item SHOULD NOT be performed, may harm
Levels of Evidence
Level A: data from multiple RCTs or MA, multiple
populations evaluated
Level B: data from single RCT or non-randomized
study, limited pop studied
Level C: consensus, case studies, or standard of
care, very limited pop studied
ESA '11 scheme will be noted as grade of evidence
A:
At least one meta-analysis, systematic review of RCTs or RCT rated as
1++ and directly applicable to the target population or a body of
evidence consisting principally of studies rated as 1+. directly
applicable to the target population and with an overall consistency of
results
B: A body of evidence including studies rated as 2++,
directly applicable to the target population and with an overall
consistency of results or extrapolated evidence from studies rated as
1++ or 1+
C: A body of evidence including studies rated as 2+,
directly applicable to the target population and with an overall
consistency of results or extrapolated evidence from studies rated as
2++
D: Evidence level 3 or 4 or extrapolated evidence from studies rated as 2+
ESA individual study 1++ to 4 ratings in source guideline
ACCP scheme will be noted as strength of rec, +/- level of evidence
Grade 1: strong recommendation
Grade 2: weak recommendation
Grade A: high quality evidence
Grade B: moderate quality evidence
Grade C: low or very low quality
ICSI scheme will be noted as strength of rec, +/- level of evidence
Strong recommendation
Weak recommendation
High quality evidence
Moderate quality evidence
Low quality evidence